CAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability. Julie M. Vose, MD, MBA
|
|
- Marcia Kelly
- 5 years ago
- Views:
Transcription
1
2 CAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability Julie M. Vose, MD, MBA
3 Relevant Disclosures Research Funding: Kite Pharma/Gilead, JUNO/Celgene, Novartis Honorarium/Ad Boards: Novartis, Kite Pharma/Gilead, JUNO/Celgene, Legend, Janssen
4 What does AutoSCT achieve in r/r DLBCL in the rituximab era? CORAL Study 3-year PFS 29% (A) Progression-free survival (PFS) according to prior rituximab (ITT) (B) PFS according to time to failure from diagnosis (ITT) 3-year PFS 29% Gisselbrecht et al. J Clin Oncol :27;
5 What does AutoSCT achieve in r/r DLBCL in the rituximab era *? 100 Relapsed or Refractory DLBCL 50 Transplant-Ineligible 50 Transplant Eligible Potential Deaths from Lymphoma 25 Respond to Salvage Therapy and ASCT 10 Patients Cured * Estimates based on Gisselbrecht et al. J Clin Oncol :27; * Assumes all patients received rituximab as part of primary therapy.
6 What can CD19-directed CAR T-Cells achieve in r/r DLBCL in the rituximab era?
7 KTE-C19 axicabtagene ciloleucel (axi-cel) CD19-directed CAR T-Cells CTL019 tisagenlecleucel (CTL019) JCAR017 lisocabtagene maraleucel (liso-cel) Kite Pharma Novartis Juno Therapeutics scfv = anti-cd19 scfv = anti-cd19 scfv = anti-cd19 CD28-CD3ζ 4-1BB-CD3ζ 4-1BB-CD3ζ FDA approved FDA approved investigational
8 CD19-directed CAR T-Cells: What is the Response Rate in r/r DLBCL?
9 JULIET Trial: Eligibility and endpoints tisagenlecleucel (CTL019) N = 111; Median follow-up, 14 mo (max, 23 mo) Key eligibility criteria 18 years of age Central confirmation of histology 2 prior lines of therapy for DLBCL PD after or ineligible for auto-sct No prior anti-cd19 therapy No active CNS involvement Endpoints Primary endpoint: best overall response rate (ORR: CR + PR) Lugano criteria used for response assessment by IRC 1 Secondary endpoints: DOR, OS, safety auto-sct, autologous stem cell transplant; CNS, central nervous system; CR, complete response; DLBCL, diffuse large B-cell lymphoma; DOR, duration of response; IRC, Independent Review Committee; ORR, overall response rate; OS, overall survival; PD, progressive disease; PR, partial response. 1. Cheson BD, et al. J Clin Oncol. 2014;32(27):
10 JULIET: Patient characteristics Patients (N = 111) Age, median (range), years 56 (22-76) 65 years, % 23 ECOG performance status 0/1, % 55/45 Central histology review Diffuse large B-cell lymphoma, % 79 Transformed follicular lymphoma, % 19 Double/triple hits in CMYC/BCL2/BCL6 genes, % 17 Cell of origin Germinal/Nongerminal center B-cell type, % 57/41 # of prior lines of antineoplastic therapy, % 2/3 / /31 / 21 IPI 2 at study entry, % 72 Refractory/relapsed to last therapy, % 55/45 Prior auto-sct, % 49 Bridging chemotherapy, n 102 Lymphodepleting chemotherapy, n 103 * from Borchmann et al. EHA 2018.
11 JULIET: Response rates Best ORR w/in 3 months of infusion, 52% (95% CI, 41%-62%): 40% CR, 12% PR *Borchmann et al. EHA 2018.
12 ZUMA-1 Trial: Eligibility and endpoints axicabtagene ciloleucel (KTE-C19) Key eligibility criteria ZUMA-1 phase 2 portion Cohort 1: patients with refractory DLBCL (n = 77) Cohort 2: patients with refractory PMBCL or transformed FL (n = 24) Key inclusion criteria No response to last CT or relapsed within 12 mos of ASCT Prior treatment with anthracycline and anti-cd20 monoclonal antibody Secondary Endpoints Assess TTR for patients with both objective response and CR Assess PR and CR at Month 3 as PFS prognostic factor TTR, time to response Locke, et al. ASCO 2018.
13 ZUMA-1: Patient Characteristics Characteristic Overall N=101 Median age, yrs (range) 58 (23-76) Male, n (%) 68 (67) ECOG PS 1, n (%) 59 (58) Disease stage III/IV, n (%) 86 (85) IPI score 3-4, n (%) 46 (46) 3 prior therapies, n (%) 70 (69) Median SPD of index lesions, mm 2 (range) 3721 (171-23, 297) Refractory to 2 lines of therapy, n (%) 77 (76) Best response as PD to last therapy, n (%) 67 (66) Relapse post-asct, n (%) 21 (21) Locke, et al. ASCO 2018.
14 ZUMA-1: Response rates Neelapu, et al. ASH 2017 Phase 2 (Primary Analysis) N = 101 Median follow-up, mo 8.7 ORR CR Best objective response, % Ongoing, % Neelapu, et al. ASH 2017.
15 TRANSCEND NHL 001 Trial: Eligibility and endpoints lisocabtagene maraleucel (liso-cel; JCAR017) N = 73*; Median follow-up, 8 mo (CORE cohort) Key eligibility criteria* DLBCL after 2 lines of therapy: DLBCL, NOS (de novo or transformed FL) High-grade B-cell lymphoma (double/triple hit) Prior SCT allowed Secondary CNS involvement allowed ECOG 0-2 No minimum lymphocyte count requirement for apheresis Response rates - ORR, CR, PR Endpoints DOR, OS, safety *CORE cohort SCT, stem cell transplant; CNS, central nervous system; CR, complete response; DLBCL, diffuse large B-cell lymphoma; DOR, duration of response; ORR, overall response rate; OS, overall survival; PR, partial response.
16 TRANSCEND: Response rates ORR* at 3 months from infusion, 59% (95% CI, 47%-70%): 45% CR, 14% PR *Includes 2 dose levels in CORE cohort *Abramson, et al. ASCO 2018.
17 CD19-directed CAR T-Cells: Are Responses Durable?
18 JULIET: Tisagenlecleucel Response Duration by Best ORR w/in 3 months of infusion (JULIET) Median DOR not reached at 14-mo median follow-up 12-mo relapse-free survival rate CR = 78.5% (95% CI, 60%-89%) CR + PR = 65% (95% CI, 49%-78%) * from Borchmann et al. EHA 2018.
19 ZUMA-1: Axicabtagene Ciloleucel Response Duration by Best Objective Response (ZUMA-1) More than one half of patients with PR progressed by Month 3 12 mo PFS for CR or PR at 3 mos: CR = 79% (95% CI, 63-88); PR = 78% (95% CI, 36-94) Neelapu SS, et al. NEJM. 2017;377:2531; Locke FL, et al. ASCO 2018.
20 TRANSCEND: lisocabtagene maraleucel Response Duration (TRANSCEND) Median DOR not reached at 8-mo median follow-up * from Abramson et al. ASCO 2018.
21 CD19-directed CAR T-Cell Therapy Summary CTL019 * tisagenlecleucel KTE-C19 ** axicabtagene ciloleucel JCAR017 *** lisocabtagene maraleucel Disease state r/r DLBCL r/r tfl r/r DLBCL r/r tfl/pmbcl r/r DLBCL r/r tfl Response evaluable pts, n Follow-up, median 14 months 15.4 months 8 months Efficacy n = 111 n = 101 N = 73 ORR / CR 52% / 40% [w/in 3 mo] 82% / 54% [best] 59% / 45% [at 3 mo] % PFS for 12 mos 78.5% 79% [88% 3 mo-cr in 6 mo] DOR (CR + PR; median) not reached 11.1 months not reached DOR (CR; median) not reached not reached not reached Safety n = 111 n = 101 n = 73 CRS 22% grade 3/4* 13% grade > 3** 1% grade > 3** Neurotoxicity 12% grade 3/4 28% grade > 3 15% grade 3/4 * Borchmann et al. EHA 2018; ** Locke, et al. ASCO 2018; Neelapau, et al. NEJM. 2017; *** Abramson et al. ASCO * Penn scale; ** Lee scale
22 Inflammatory state Factors That Influence Treatment Success and Failure to CAR T Cell Therapy: A Hypothesized Model Manufacturing starting material Product fitness: T cell expansion capability T cell polyfunctionality Number of specialized T cells infused Conditioning and concomitant medications Tumor burden Tumor immune microenvironment CAR functional avidity Tumor cell biology PK/PD profile CAR, chimeric antigen receptor; PD, pharmacodynamics; PK, pharmacokinetics. Clinical efficacy and toxicity Adapted from Locke et al SITC 2018 #P212 22
23 In ZUMA-1 CAR T Cell Expansion Associated With Response Objective Response Rate (ORR) CAR expansion was significantly associated with response (P <.001), with an AUC Day0-28 that was 5.4 times as high among patients with a response as among those who did not have a response CAR AUC Day0-28 is defined as cumulative levels of CAR+ cells/μl of blood over the first 28 days post axi-cel AUC fold change is shown for patients with vs. without response Locke et al ASCO 2017 #
24 Post-Infusion CAR Peak Levels Pre-Infusion Polyfunctional Strength Normalized CAR Peak + PSI CAR Peak Levels In Vivo and Polyfunctional Strength Index Associated With Objective Response CAR Peak P =.0326 a PSI P =.0119 a CAR Peak + PSI P =.0046 a NR R NR a Mann-Whitney U Test. CAR, chimeric antigen receptor; NR, nonresponder; PSI, polyfunctional strength index; R, responder. R NR R Rossi et al AACR 2017 #
25 Association Between Immunosign 21 Score Measured Before CAR T Cell Treatment and Clinical Outcome a A high Immunosign 21 score was associated with objective response at a minimum follow-up of 9 months (P =.012) In a sensitivity analysis, which included the delayed responder, the association between a high Immunosign 21 score and objective response had a P =.053 a This analysis was performed on samples from 25 patients treated with axi-cel with a minimum follow-up of 9 months. One patient subsequently converted from a nonresponder to a responder at 12-month follow-up. b Cutoff was arbitrarily defined as the 25th percentile of the observed scores among samples. Rossi et al AACR 2018 #LB
26 Differences in Expression of Immunosign 21 Genes Measured Before CAR T Cell Treatment in Responders vs Nonresponders a a This analysis was performed on samples from 25 patients treated with axi-cel with a minimum follow-up of 9 months. One patient subsequently converted from a nonresponder to a responder at 12-month follow-up. Rossi et al AACR 2018 #LB
27 Treatment with Axi-Cel Results in Rapid and Dramatic Changes in the Tumor Immune Microenvironment Checkpoints IFN related Effectors Proliferative Chemokines Galon et al, ASCO 2017 PD-L1 CTLA4 Top transcripts from a pre-specified 43 immune gene panel upregulated in tumor 7-21 days after treatment. IDO1 and other genes not in the 43 panel are pending. LAG3 TNFRSF18 ICOS IRF1 STAT1 STAT4 IFNg CD8A GNLY GZMA GZMM GZMB GZMH IL15 CXCL9 CCL2 CCL5 Galon et al ASCO 2017 #
28 Analysis of B Cell and Immune-Related Molecules at Progression Identifies Relapse with CD19+ or CD19- Tumor cells Progression Biopsies N=21 CD19 (n=21) CD19+ 14/21 (67) CD19-7/21 (33) PD-L1 (n=19) PD-L1+ 9/14 (64) PD-L1-4/14 (29) PD-L1 N/E 1/14 (7) PD-L1+ 4/7 (57) PD-L1-2/7 (29) PD-L1 N/E 1/7 (14) Post-progression tumor biopsies (21 evaluable patients) - 33% were CD % were PD-L1+ At Baseline, 94% (16/17) of evaluable patients were CD19+ Example CD19+ relapse Example CD19- relapse Baseline and post-progression samples not obtained from the same lesions. PD-L1, programmed death ligand CD19 RNA splice variants identified In DLBCL relapse biopsies Adapted from Neelapu et al ASH 2018 #578 28
29 Conclusions In ZUMA-1 ~20% of treated patients were primary refractory to anti-cd19 CAR T cell therapy Mechanisms of primary treatment related failure ascribable to: o Product T cell fitness o CAR T cell function in product o Immune exclusionary tumor microenvironment In ZUMA-1 ~35% of treated patients experienced a secondary treatmentrelated failure Mechanisms of secondary treatment-related failure ascribable to: o High tumor burden o Rapid upregulation of immune checkpoints o CD19 target antigen loss 29
30 Peak Cytokine Levels Correlate with Response to Anti-CD19 CAR T Therapy Kochenderfer JN et al. J Clin Oncol. 2017;35(16):
31 JCAR017 (lisocabtagene maraleucel; liso-cel): CD19-Targeted CAR T-cell Tumor cell Patient s PBMCs Tumor antigen Epitope Immunomagnetic selection Lentivirus transduction Transmembrane domain scfv Spacer Expansion Formulated at specified composition of CD4 + and CD8 + CAR + T cells Administered at precise doses of CD4 + and CD8 + CAR + T cells CAR + CD8 + T cell Intracellular costimulatory domain Signaling sequence CD8 + (targets tumor) CD4 + (targets tumor, supports persistence) CAR + CD4 + Other PBMC Cell Types EF1p CD19 scfv murine monoclonal FMC63 Transmembrane domain Spacer Signaling domain Transduction marker VL linker VH CD28tm 4-1BB CD3ζ T2A huegfrt 3 LTR Siddiqi, ASH 2017
32 Units Tumor Burden, Baseline Markers of Inflammation, and Inflammatory Cytokines May Trend Lower in Patients with Durable Response No Response at 3 Months Response (CR/PR) at 3 Months 0.1 a Similar result seen when analyzed at DL2 alone. Pre-LD Parameter a Ferritin and D-dimer measured in μg/l, CRP and SAA-1 measured in mg/l; all cytokines measured in pg/ml p < 0.05 for all parameters except SPD (p = 0.12) Data as of October 9, 2017 Siddiqi, ASH 2017
33 Estimated Probabilities Preliminary Logistic Modeling Data Suggest a Therapeutic Window Exists that Could Limit Toxicity and Optimize Efficacy Low expansion Potential tumor-mediated suppression Potential product and/or patient characteristics Identify at risk population and investigate strategies to enhance expansion High expansion High tumor burden and inflammatory cytokines Potential product and/or patient characteristics Identify at risk population and investigate strategies to limit expansion 1.0 Target Expansion Any CRS Any NT Gr 3-4 NT ORR M3 Response CRS, cytokine release syndrome; NT, neurotoxicity; ORR, overall response rate; M3, month 3 Increasing Maximum CAR T Cell Expansion Siddiqi, ASH 2017 Data as of October 9, 2017
34
35
36
37 Conclusions CD 19+ CAR-T cell for DLBCL CR rates 30-50% If patients in CR at 6 months post-car-t many maintain response Long term responders some understanding: Lower tumor volume Lower CRP and ferritin less inflammation Cytokine profile in responders Hi PD-1 may decrease the response rates and/or increase early relapse. Combinations during or after CAR-T may help to decrease relapse rates
CAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationBackground. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationChimeric Antigen Receptor - CAR T cell therapy. Frederick L. Locke, MD 2/17/2017
Chimeric Antigen Receptor - CAR T cell therapy Frederick L. Locke, MD 2/17/2017 T cells are immune system cells that normally fight infection Each T cell recognizes a specific target T cells multiply and
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationExploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies
Exploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies Maurice Alexander, PharmD, BCOP, CPP Clinical Specialist, Blood and Marrow Transplant UNC Bone Marrow
More informationCD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma
biology of neoplasia CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma Caron A. Jacobson, MD 1 ABSTRACT PURPOSE Anti-CD19 directed chimeric antigen receptor (CAR) T-cell
More informationHighlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting
August 2017 Volume 15, Issue 8, Supplement 8 A SPECIAL MEETING REVIEW EDITION Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting A Review of
More informationImmunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy
Immunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy This transcript has been edited for style and clarity and includes all slides from the presentation. This
More informationChimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma
Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma Stephen J. Schuster, M.D. Director, Lymphoma Program & Lymphoma Translational Research, Abramson Cancer
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationB-Cell NHL and Hodgkin s Disease: Biologicals, Checkpoint Inhibitors, CAR-T cells
B-Cell NHL and Hodgkin s Disease: Biologicals, Checkpoint Inhibitors, CAR-T cells Eduardo M. Sotomayor, MD Director, George Washington Cancer Center Professor, Department of Medicine George Washington
More informationImmunotherapy in Cancer: turning T cells against cancer
Immunotherapy in Cancer: turning T cells against cancer Frederick L. Locke, MD Director, Immune Cell Therapy Program Department of Blood and Marrow Transplant Cellular Immunotherapy Moffitt Cancer Center
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationCAR T-Cell Therapy for Your Patients: What You Need To Know
CAR T-Cell Therapy for Your Patients: What You Need To Know Marco L. Davila, MD, PhD Associate Member, Blood & Marrow Transplantation and Cellular Immunotherapy Medical Director Cell Therapy Facility H.
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationCytokine Release Syndrome and Neurotoxicity: Ongoing Efforts to Enhance Safety. Sattva S. Neelapu, MD
Cytokine Release Syndrome and Neurotoxicity: Ongoing Efforts to Enhance Safety Sattva S. Neelapu, MD Disclosures Research support from Kite, Merck, BMS, Cellectis, Poseida, Karus, Acerta Advisory Board
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationClinical Advances in Lymphoma
Conflicts of Interest Clinical Advances in Lymphoma Alex F. Herrera, MD Assistant t Professor Department of Hematology and HCT City of Hope BMS research funding (institutional), consultancy Genentech research
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationCurrent Applications and Future Directions of CAR-T cell therapies for B-cell Malignancies
Current Applications and Future Directions of CAR-T cell therapies for B-cell Malignancies Nirav Shah, MD MSHP Assistant Professor of Medicine Medical College of Wisconsin 1 Financial Disclosure I currently
More informationSupplemental Information. Phase 1 Results of ZUMA-1: A Multicenter Study. of KTE-C19 Anti-CD19 CAR T Cell Therapy. in Refractory Aggressive Lymphoma
YMTHE, Volume 25 Supplemental Information Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma Frederick L. Locke, Sattva S. Neelapu,
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationLymphoma and CLL EHA Madrid Professor John G Gribben Centre for Haemato-Oncology Barts Cancer Institute, London, UK
Lymphoma and CLL EHA Madrid 2017 Professor John G Gribben Centre for Haemato-Oncology Barts Cancer Institute, London, UK Conflicts of Interest J Gribben I have the following financial relationships to
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationRelapsed/Refractory Diffuse Large B-Cell Lymphoma John Kuruvilla, MD Princess Margaret Cancer Centre University of Toronto
Relapsed/Refractory Diffuse Large B-Cell Lymphoma John Kuruvilla, MD Princess Margaret Cancer Centre University of Toronto Disclosures Research Support Employee Leukemia and Lymphoma Society US, Rasch
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationInterim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience
Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience MD. Caballero, Hospital Universitario, Salamanca, Spain. Chair of The GEL/TAMO Group Menton,9 april 2010 Disclosures for Dolores Caballero
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationEstimand and analysis considerations of phase 3 clinical trials involving CAR-T A case study in lymphoma
Estimand and analysis considerations of phase 3 clinical trials involving CAR-T A case study in lymphoma Michael Yiyun Zhang, on behalf of Novartis Team 2018 ASA Biopharmaceutical Section Regulatory-Industry
More informationSevere Neurotoxicity in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study): Analysis of Patient, Protocol and Product Attributes
Severe Neurotoxicity in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study): Analysis of Patient, Protocol and Product Attributes Mark J. Gilbert, MD Chief Medical Officer, Juno Therapeutics, Inc.
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More informationManaging Patients Undergoing CD19 CAR-T Therapy
Managing Patients Undergoing CD19 CAR-T Therapy June 7, 2018 Dr. Ronan Foley, MD, FRCPC and Jennifer Wiernikowski, MN, NP-Adult, CON(C) Juravinski Hospital Hamilton ON Speaker Disclosures Dr Foley: Advisory
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationFirenze, settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo
Firenze, 22-23 settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo Hematology University Hospital Città della Salute e della Scienza Torino, Italy Disclosures Umberto Vitolo Research Support/P.I. Employee
More informationPOST ICML Indolent lymphomas relapse treatment
POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationChimeric Antigen Receptors (CAR)
CAR Therapy In CLL Chimeric Antigen Receptors (CAR) 4-1BB (CD137) Costimulatory Domains: 0 1 2 PENN: 4-1BB MSKCC: CD28 USCD: CD28 Porter, D.L. et al Sci Trans Med 7:1-12, 2015 CD19 CAR T Cell Therapy For
More informationNew Therapies and Current Management of Follicular Lymphoma
New Therapies and Current Management of Follicular Lymphoma Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationASH POSTER: LYMRIT UPDATE
ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationPeripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation
Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationB Kahl 1, M Hamadani 2, P Caimi 3, E Reid 4, K Havenith 5, S He 6, JM Feingold 6, O O Connor 7
First Clinical Results of ADCT-42, a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate (ADC), in Relapsed/Refractory B-cell Lineage Non-Hodgkin Lymphoma B Kahl 1, M Hamadani 2, P Caimi 3, E Reid
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationEngineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL
Engineering an Immunity to Cancer: A New Era of Adoptive Cellular Therapy with Tisagenlecleucel (Kymriah) in Pediatric ALL Diana Schreier, Pharm.D., M.B.A. Pharmacy Grand Rounds October 17, 2017 2017 MFMER
More informationTitle: Chimeric Antigen Receptor T Cell Therapy in Presenters: Lymphoma and Leukemia Date: Elizabeth Budde, MD, PhD
Title: Chimeric Antigen Receptor T Cell Therapy in Presenters: Lymphoma and Leukemia Date: Tu m o r T c e ll Elizabeth Budde, MD, PhD Department of Hematology & HCT T Cell Therapeutics Research Laboratory
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationTitle: Chimeric Antigen Receptor T-Cell Therapy: Presenters: Promises and Challenges Date: Elizabeth Budde, MD, PhD
Title: Chimeric Antigen Receptor T-Cell Therapy: Presenters: Promises and Challenges Date: Elizabeth Budde, MD, PhD Department of Hematology & HCT T Cell Therapeutics Research Laboratory Beckman Research
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationCAR T CELL IMMUNOTHERAPY FOR ALL. Stephan Grupp, MD, PhD
CAR T CELL IMMUNOTHERAPY FOR ALL Stephan Grupp, MD, PhD Disclosures Research and/or clinical trial support from Novartis, Servier, Vertex and Kite Study steering committees, consulting, or scientific advisory
More informationTarGeting B-Cell Diseases
TarGeting B-Cell Diseases Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationTolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL
Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced and NHL Loretta Nastoupil, MD 1, Matthew A. Lunning, DO 2, Julie
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationCAR T Cell Therapy: What, When, How. Elizabeth Budde, MD, PhD Dept. of Hematology & HCT Beckman research Institute
CAR T Cell Therapy: What, When, How Elizabeth Budde, MD, PhD Dept. of Hematology & HCT Beckman research Institute March 23, 2019 DISCLOSURES Advisory board: Promab Biotechnologies; Gilead, Roche Consultancy/Speaker
More informationBrentuximab Vedotin in Lymphomas
New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationImmunotherapy in haematological malignancies. Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona
Immunotherapy in haematological malignancies Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Roche Celgene Mundipharma Janssen Gilead Bayer Millenium What
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationParticipating Institutions Insitut Gustave Roussy, Villejuif, France Institut Bergonie, Bourdeaux, France. Sponsor Epizyme, Inc
Phase 1 Study of EPZ-6438 (E7438), an Enhancer of Zeste Homolog-2 (EZH2) Inhibitor: Dose Determination and Preliminary Activity in Non-Hodgkin Lymphoma V. Ribrag, J-C. Soria, B. Thomson, L. Reyderman,
More informationAdoptive Cell Therapy: Treating Cancer
Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three
More information